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1063-58 A Randomized Placebo-Controlled Trial of Abciximab 
for Prevention of In-Stent Restenosis in Diabetic 
Patients After Coronary Stenting
Wai-Hong Chen, Upendra Kaul, Sum-Kin Leung, Yuk-Kong Lau, Huay-Cheem Tan, 
Albert Wai-Suen Leung, Michael Kang-Yin Lee, Shu-Kin Li, William Ng, Pui-Yin Lee, 
Chu-Pak Lau, Queen Mary Hospital, Hong Kong, People's Republic of China, Batra 
Hospital & Medical Research Centre, New Delhi, India
Background: Coronary stenting is associated with a high incidence of restenosis in
patients with diabetes mellitus (DM). Recent data suggest that DM patients treated with
abciximab have a lower rate of target vessel revascularization. 
Methods: In a prospective double-blind trial, we randomly assigned DM patients under-
going non-urgent coronary stenting to receive abciximab with initial heparin bolus of 50
U/kg or placebo with initial heparin bolus of 70 U/kg. All patients received aspirin and clo-
pidogrel before the procedure. The primary endpoint was angiographic restenosis at 6
months. The secondary endpoint was death, myocardial infarction (MI), or target lesion
revascularization (TLR) at 6 months. 
Results: Two hundred and forty-eight patients were enrolled. The baseline characteris-
tics were matched between the two groups except for a higher incidence of patients
treated with oral hypoglycemic drugs (80% vs 68.3%; p=0.04) in the abciximab group.
Angiographic follow-up was completed in 224 patients (90.3%). 
Conclusion
Abciximab does not reduce angiographic restenosis or TLR in DM patients undergoing
non-urgent coronary stenting.
1063-59 Preprocedural Statin Medication Reduces the Risk for 
PeriProcedural Myocardial Infarctions in Patients With 
Stent Implantation Independent of the Cholesterol Level
Michael Haude, Joerg Herrmann, Lothar Volbracht, Thomas Konorza, Christoph 
Altmann, Rainer Schulz, Gerd Heusch, Raimund Erbel, University Hospital Essen, 
Essen, Germany, Mayo Clinic, Rochester, MN
Background: Pleiotropic effects of HMG-CoA reductase inhibitors (statins) include anti-
thrombotic and anti-inflammatory aspects. Statins reduce stenting-related myocardial
injury (MI)caused by microembolisations of platelet aggregates and plaque debris
together with inflammation. It is unclear whether these effects depend on lipid-lowering or
pleiotropic properties of statins. Thus, we tested whether statin pretreatment limits the
extent of MI independent of the achieved cholesterol level.
Methods: We stratified 1218 consecutive patients (pts) with uncomplicated stenting
according to their pre-procedural status of statin therapy (1012 statin-pos. and 206 statin-
neg. pts). MI was assessed by analysis of creatine kinase (CK; upper limit of normal
(ULN) 80 IU/l), CK-MB (threshold ULN >8% of CK fraction) and cardiac troponin I (TI;
threshold 0.1 ug/L) before and 6, 12, and 24 hours after stenting.
Results: Maximum CK, CK-MB, and TI elevations were significantly larger in statin-neg.
pts (68±62 versus 52±46 IU/L; 24±20 versus 18±18 IU/L; and 0.46±0.48 versus
0.38±0.42ug/L; all p<0.001). Statin pretreatment reduced relative risk (RRR) for postint-
erventional ischemia marker elevation for all cut-off criteria separating small, intermedi-
ate and large periprocedural MI independent of the LDL cholesterol level (Fig.).
Conclusions: Pre-procedural statin therapy reduces stenting-related MI independent of
the cholesterol level, supporting the importance of pleiotropic effects of statins.
1063-60 Oral Rapamune to Inhibit Restenosis in Patients With 
Multi De Novo Coronary Lesions Requiring Stenting
Ron Waksman, Augusto D. Pichard, Andrew E. Ajani, Rebecca Torguson, Ellen Pinnow, 
Louise Gambone, Natalie Gevorkian, Maureen C. Abbott, Lowell F. Satler, Kenneth M. 
Kent, Joseph Lindsay, Washington Hospital Center, Washington, DC
Background: Drug-eluting stents (utilizing antiproliferative agents such as Rapamune
(R)) have shown the ability to limit restenosis. Oral Rapamune® is an alternative delivery
strategy that can target multistenosed coronary vessels and may potentially lower costs
and vessel toxicity.
Methods: ORBIT (Oral Rapamune to Inhibit Restenosis) is an open label study of 60
patients (pts) with de novo coronary artery stenosis treated with stent implantation in up
to 2 vessels. The first 30 pts received R 2 mg/day for 30 days, and the second cohort of
30 pts received R 5 mg/day for 30 days. The loading dose for both regimens was 5 mg
given either immediately prior to or after the intervention. Patients underwent clinical and
angiographic follow-up.
Results: Angiographic success was achieved in all pts. Drug therapy was discontinued in
3 pts in the 2 mg group and 9 pts in the 5 mg group due to skin rash, diarrhea, mouth
ulcers, or fatigue (or a combination of these symptoms). There were no biological or bio-
chemical adverse affects. There was no evidence of dose effect on angiographic and clin-
ical outcome.
Conclusions: Oral Rapamune administration for the prevention of restenosis is safe, is
tolerable for the vast majority of patients, and is associated with lower rates of restenosis
and clinical events at 6 months. 
1063-61 Angiomax Versus Heparin as an Antithrombotic Agent 
in Patients Undergoing Percutaneous Coronary 
Intervention in Saphenous Vein Bypass Grafts
Seung-Woon Rha, Ron Waksman, George Aggrey, Afework GebreEyesus, Rebecca 
Torguson, Mohan Nandalur, Pramod K. Kuchulakanti, Rajbabu Pakala, Ellen E. Pinnow, 
Joseph Lindsay, Washington Hospital Center, Washington, DC
Background: Bivalirudin (Angiomax®) is a thrombin-specific anticoagulant approved for
use in percutaneous coronary intervention (PCI). This study aimed to compare the effi-
cacy and safety of Bivalirudin with Heparin in patients (pts) undergoing PCI in saphenous
vein bypass grafts (SVG).
Methods: All patients were treated with Bivalirudin (0.75 mg/kg bolus and 1.75 mg/kg/hr
infusion) or Heparin as the antithrombotic agent during standard PCI in SVGs. All pts
received aspirin and clopidogrel and were recommended to continue for at least 1 year.
Periprocedural complications and in-hospital events of both groups were compared.
Results: Overall 93 pts (131 lesions) in Angiomax group and 1890 pts (2718 lesions) in
Heparin group were included for the study. Baseline clinical characteristics were similar in
both groups. Procedural and in-hospital events were similar, except for vascular compli-
cations including major hematoma were significantly higher in Heparin group.
Conclusion: Angiomax as a single antithrombotic agent in pts undergoing standard PCI
in SVGs is clinically safe and is associated with significantly low vascular complications
compared to Heparin.
Abciximab Placebo p
Angiographic restenosis, % 29 25 0.46
Late loss, mm 1.13±0.59 1.12±0.59 0.83
Loss index 0.67±0.41 0.66±0.39 0.71
Death, % 0 0.8 0.50
MI, % 4.0 6.5 0.41
TLR, % 15.4 13.4 0.64
Death, MI, or TLR, % 20.8 23.6 0.65
Dosages 2 mg 5 mg
N 30 (pts)
49 (lesions)
30 (pts)
37 (lesions
P value
Reference Vessel Diameter (mm) 3.00+/-0.44 3.09+/-0.51 0.36
Lesion Length (mm) 14.12+/-6.75 13.57+/-4.84 0.67
Lesion/pt 1.6+/-0.5 1.3+/-0.5 0.02
R level at 30 days 6.4+/-4.2 18.7+/-4.2 <0.001
Binary Restenosis Rate (%) 7.1% 6.9% 0.97
Late Loss 0.60+/-0.61 0.68+/-0.56 0.56
In-hospital clinical outcomes of Angiomax vs. Heparin in SVG intervention
Clinical Events Angiomax 
(N= 93 pts / 131 
lesions)
Heparin
(N=1890 pts / 2718 
lesions)
P-
Value
Bleeding 
Complications, (%)
Major 
hematoma
(>4cm)
0.0 1.1 0.035
Major bleeding 2.2 3.3 0.551
Hematocrit 
Drop > 15
1.2 2.5 0.438
Transfusion 6.5 6.1 0.893
Vascular Complications,(%) 0.0 4.9 0.028
In-hospital TVR-MACE
(Death, Q-MI, TVR, %)
2.2 1.7 0.768
